Skip To Main Content
Barbara Pistilli on Muck Rack

Barbara Pistilli

As seen in: Color Research & Application, Nature, MDPI, JAMA Oncology, Cell Press, Cancer Epidemiology, Biomarkers & Prevention, The Bakersfield Californian, ONCOLOGY journal, OncLive, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Antibody-drug conjugates in precision oncology

|
By Barbara Pistilli, Raffaele Colombo, Maria Fernanda Mosele, Sarat Chandarlapaty
| Cell Press Verified
Keywords antibody-drug conjugates ADCs precision medicine ADC toxicity mechanisms of action mechanisms of resistance ADC combinations Introduction Antibody-drug conjugates (ADCs) are innovative and complex therapeutic entities that have transformed cancer treatment.1,2 Initial clinical benefit was achieved in hematological malignancies, with gemtuzumab ozogamicin being the first ADC to receive Food and Drug Administration (FDA) accelerated approval in 2000 for adults with CD33-positive acute...
Open in Who Shared Issue with article?

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

|
By Prescribing Exercise, Nicholas Hornstein, Barbara Pistilli
| ONCOLOGY journal Verified
Background The PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM inhibition with ET plus CDK4/6i after progression may restore sensitivity, and ideally, would provide clinical benefit independent of direct PI3K-pathway alterations. Gedatolisib, a highly potent multitarget inhibitor of all class I PI3K isoforms plus mTORC1 and mTORC2, comprehensively blocks PAM regardless of PIK3CA status.
Open in Who Shared Issue with article?

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

|
By David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia L. Kannouche, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin Verified, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Akoli Koudou, Valerie Camara, Abdelhafidh Belarkemi, alexis klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
| Cell Press Verified
Keywords ADC Dato-DXd mechanism of action response resistance NSCLC TROP2 internalization Introduction In 2022, lung cancer was the most frequently diagnosed cancer, with about 2.5 million new cases, and the leading cause of cancer death, with 1.8 million deaths worldwide.1 Several targeting therapies have been developed and approved over the past years for the treatment of metastatic lung cancer, particularly for non-small cell lung cancer (NSCLC); however, only 35%–40% of patients with...
Open in Who Shared Issue with article?
See all 17 licensed articles (19 Total)